Preview image. Unlock full-res
A two-part section comparing brand-name GLP-1 costs to Heva pricing, then presenting Semaglutide and Tirzepatide trial statistics in two columns.
Summary
Top block contrasts $1,300+ brand-name GLP-1 costs with Heva's $149/month programs; bottom block shows NEJM trial stats for Semaglutide and Tirzepatide.
Visual description
Cream background in two stacked sections. Top centered: "THE HEVA DIFFERENCE" label, large serif headline citing Wegovy and Zepbound at $1,300+/month italicized, body copy about Heva compounded programs from $149/month with physician supervision and shipping, and trademark disclaimer. Bottom left-aligned: "WHAT THE RESEARCH SHOWS" label, serif heading about prescribed medications by the numbers. Two columns list SEMAGLUTIDE (STEP-1 trial) and TIRZEPATIDE (SURMOUNT-1 trial) with three percentage stats each. Fine-print citations and individual-results disclaimer at bottom.
Key takeaway
Pairing a price-anchor comparison with peer-reviewed trial numbers answers both "why cheaper?" and "does it work?" in one scroll. Italicizing the competitor price draws the eye without shouting.
Reuse notes
For compounded or alternative therapeutics needing credibility beyond price. Legal disclaimers are essential. Data-dense bottom section needs generous line height.
